{
    "nctId": "NCT00101972",
    "briefTitle": "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma",
    "officialTitle": "A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 53,
    "primaryOutcomeMeasure": "Toxicity by CTCAE",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma\n\n  * Metastatic or recurrent disease\n  * Not curable by standard therapies\n* Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease\n\n  * Patients with colorectal or breast adenocarcinoma must have failed at least 2 prior therapies\n  * Must have had at least stable disease for 3 months while on last treatment prior to most recent disease progression\n* Meets 1 of the following criteria:\n\n  * At least 1 measurable site of disease \u2265 2 cm by radiography\n  * Evaluable disease that could be reliably and consistently followed, as deemed by the principal investigator\n* RAAG12 expression confirmed\\* by immunohistochemistry NOTE: \\*Not required for patients with colon, pancreatic, or gastric adenocarcinoma\n* No evidence of residual or recurrent CNS metastases\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Not specified\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* More than 3 months\n\nHematopoietic\n\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 9.0 g/dL (transfusions allowed)\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n\nHepatic\n\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* AST and ALT \u2264 2.5 times ULN\n* Alkaline phosphatase \u2264 2.5 times ULN\n* \u03b3-glutamyl transferase \u2264 2.5 times ULN\n* Adequate hepatic function sufficient to undergo study therapy\n\nRenal\n\n* Creatinine \\< 1.5 mg/dL\n* Adequate renal function sufficient to undergo study therapy\n\nCardiovascular\n\n* No New York Heart Association class III or IV heart disease\n* No thrombosis within the past 3 months, including any of the following:\n\n  * Deep vein thrombosis\n  * Myocardial infarction\n  * Stroke\n* Adequate cardiac function sufficient to undergo study therapy\n\nPulmonary\n\n* No pulmonary embolism within the past 3 months\n* No significant pulmonary compromise, particularly dependence on supplemental oxygen on an as-needed or continuous basis\n* Adequate pulmonary function sufficient to undergo study therapy\n\nImmunologic\n\n* No active viral, bacterial or systemic fungal infection requiring parenteral therapy within the past 4 weeks\n* No history of chronic or recurrent infection requiring continual antiviral, antifungal, or antibacterial agents\n* No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in study drug\n\nOther\n\n* Amylase and lipase normal\n* No other primary malignancy within the past 3 years except for the following:\n\n  * Treated non-melanoma skin cancer\n  * Carcinoma in situ of the cervix by biopsy\n  * Squamous intraepithelial lesion of the cervix by PAP smear\n  * Localized prostate cancer (Gleason score \\< 6)\n  * Resected melanoma in situ\n* No other serious medical condition that would preclude study participation\n* No dementia or altered mental status that would preclude giving informed consent\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 3 half-lives since prior monoclonal antibody therapy\n* No concurrent vaccinations\n* No concurrent prophylactic hematologic growth factors\n\nChemotherapy\n\n* At least 4 weeks since prior chemotherapy\n\nEndocrine therapy\n\n* No concurrent steroids except for the following:\n\n  * Inhaled, ophthalmic, or nasal steroids\n  * Stable dose of oral prednisone (or equivalent) \u2264 10 mg/day\n\nRadiotherapy\n\n* At least 4 weeks since prior radiotherapy\n\nSurgery\n\n* More than 4 weeks since prior major surgery\n\nOther\n\n* More than 4 weeks since prior investigational agents\n* Prior oral antiviral, antifungal, or antibacterial therapy allowed provided therapy was completed within the past week\n* No other concurrent antineoplastic therapy\n* No concurrent immunosuppressive medications\n* No other concurrent investigational agents\n* No concurrent vitamins except those approved by the medical monitor\n\n  * Concurrent daily multivitamin allowed\n* Concurrent bisphosphonates allowed provided patient is on stable dose for \u2265 1 month prior to study entry",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}